BIIB 100
Alternative Names: BIIB-100; KPT 350Latest Information Update: 08 Jul 2025
At a glance
- Originator Karyopharm Therapeutics
- Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Fluorinated hydrocarbons; Hydrazines; Neuroprotectants; Small molecules; Triazoles
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Unspecified; Uveal melanoma
- Discontinued Brain injuries; Duchenne muscular dystrophy; Epilepsy; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Uveal melanoma presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)
- 04 Apr 2025 Preclinical trials in Uveal melanoma in USA (PO), prior to April 2025
- 31 Dec 2024 Preclinical trials in Unspecified in USA (PO)